Monte Rosa Therapeutics, Inc.

GLUENASDAQHealthcare● Active

$17.00

+$0.63(+3.85%)

Market Cap$1.1B

P/E Ratio—

52W High$25.77

52W Low$4.12

Avg Volume993K

Open$16.56

Beta1.60

Overview

Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Monte Rosa Therapeutics, Inc. (GLUE) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · GLUE · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-1.86Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)$43.0MFull revenue history

Dividend YieldNo DividendDividend history

Shares Outstanding83.1MShares outstanding history

Next EarningsAug 6, 2026Est.Earnings history

Explore Monte Rosa Therapeutics, Inc. Data

Market Cap$1.1B

Analyst Forecast$32 · Buy

DividendsNo Dividend

Revenue$123.7M+63.54%

EarningsEPS $-0.46+53.06%

PE Ratio—

Financial Snapshot

Full Financials

FY 2025Revenue$123.7M▲ +63.54% YoY

202320242025

FY 2025Net Income-$38.6M▲ +46.87% YoY

202320242025

FY 2025EPS$-0.46▲ +53.06% YoY

202320242025

TTM:Revenue: $43.0MNet Income: -$130.0MEPS: $-1.86View income statement →

Analyst Ratings & Price Target

Full Forecast

Buy9 analysts

Strong Buy

Buy

Hold

Sell

Strong Sell

12-Month Price Target

$22.00Low

$17.00Current

$31.75Avg Target86.76% upside

$37.00High

Total: 9 · Buy rate: 77.8%

The GLUE analyst consensus is Buy, based on ratings from 9 Wall Street analysts over the past 3 months. The average 12-month price target is $31.75, representing +86.76% upside from the current price of $17.00.

Competitors & Peers

#TickerCompanyPriceChangeMkt Cap

GLUE

Monte Rosa Therapeutics, Inc.

$17.00+3.85%$1.1B #2

ARVN

Arvinas, Inc.

$7.15-3.64%$461.3M #3

AVBP

ArriVent BioPharma, Inc. Common Stock

$30.50+0.49%$1.4B #4

DAWN

Day One Biopharmaceuticals, Inc.

$21.53+0.00%$2.2B #5

DNA

Ginkgo Bioworks Holdings, Inc.

$8.09-1.58%$528.5M #6

GERN

Geron Corporation

$1.13-3.42%$724.9M

Stock Performance

Full History

1D+2.78%

1W-5.85%

1M-13.23%

3M-5.48%

YTD+7.30%

1Y+241.97%

5Y-20.56%

About Monte Rosa Therapeutics, Inc.

CEOMarkus Warmuth

IPO DateJun 24, 2021

Employees142

CountryUS

Websitemonterosatx.com

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms t…

Biotechnology HealthcareNASDAQUS

About Stock Overview & Key Data

Monte Rosa Therapeutics, Inc. (GLUE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 24, 2021. As of the latest trading session, GLUE stock price is $17.00, with a market capitalization of $1.1B. The stock has returned +241.97% over the past 12 months and +7.30% year-to-date.

According to 9 Wall Street analysts, the consensus rating for Monte Rosa Therapeutics, Inc. stock is Buy, with an average 12-month price target of $31.75. In fiscal year 2025, Monte Rosa Therapeutics, Inc. reported revenue of $123.7M and net income of -$38.6M. For detailed data — including Monte Rosa Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Monte Rosa Therapeutics, Inc. (GLUE) stock price is $17.00. The stock is traded on NASDAQ under the ticker symbol GLUE. The 52-week range is $4.12 – $25.77.

GLUE stock priceGLUE quote todaylive ticker

Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice